"Oncolytic Viruses" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumor-selective, replication competent VIRUSES that have antineoplastic effects. This is achieved by producing cytotoxicity-enhancing proteins and/or eliciting an antitumor immune response. They are genetically engineered so that they can replicate in CANCER cells but not in normal cells, and are used in ONCOLYTIC VIROTHERAPY.
| Descriptor ID |
D050504
|
| MeSH Number(s) |
B04.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oncolytic Viruses".
Below are MeSH descriptors whose meaning is more specific than "Oncolytic Viruses".
This graph shows the total number of publications written about "Oncolytic Viruses" by people in this website by year, and whether "Oncolytic Viruses" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 3 | 0 | 3 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 0 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 0 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 2 | 0 | 2 |
| 2024 | 1 | 1 | 2 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncolytic Viruses" by people in Profiles.
-
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. Nature. 2025 Jul; 643(8070):219-229.
-
IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity. Nat Commun. 2025 Apr 24; 16(1):3874.
-
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer. 2024 Dec 09; 12(12).
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 04; 25(4):488-500.
-
Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models. J Transl Med. 2023 07 06; 21(1):444.
-
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790.
-
An Ion-Enhanced Oncolytic Virus-Like Nanoparticle for Tumor Immunotherapy. Angew Chem Int Ed Engl. 2022 11 07; 61(45):e202210487.
-
Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy. J Immunother Cancer. 2021 07; 9(7).
-
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).
-
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021 03 19; 4(1):368.